tradingkey.logo
搜尋

Harvard Bioscience Inc

HBIO
添加自選
6.100USD
+0.010+0.16%
收盤 07-31 16:00美東報價延遲15分鐘
27.51M總市值
虧損本益比TTM

關於 Harvard Bioscience Inc 公司

Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.

Harvard Bioscience Inc簡介

公司代碼HBIO
公司名稱Harvard Bioscience Inc
上市日期Oct 21, 2013
CEODuke (John D)
員工數量330
證券類型Ordinary Share
年結日Oct 21
公司地址84 October Hill Rd
城市HOLLISTON
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編01746-1371
電話15088938999
網址https://www.harvardbioscience.com/
公司代碼HBIO
上市日期Oct 21, 2013
CEODuke (John D)

Harvard Bioscience Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Ms. Katherine Anne Eade, J.D.
Ms. Katherine Anne Eade, J.D.
Lead Independent Director
Lead Independent Director
58.67K
+28.22%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
27.56K
+60.08%
Mr. Stephen J. DeNelsky
Mr. Stephen J. DeNelsky
Director
Director
26.56K
+62.34%
Mr. Robert Benson
Mr. Robert Benson
Independent Director
Independent Director
--
--
Mr. Sandy Martin
Mr. Sandy Martin
Investor Relations
Investor Relations
--
--
Mr. Mark Frost
Mr. Mark Frost
Interim Chief Financial Officer, Treasurer
Interim Chief Financial Officer, Treasurer
--
--
Mr. John D. Duke
Mr. John D. Duke
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Ms. Katherine Anne Eade, J.D.
Ms. Katherine Anne Eade, J.D.
Lead Independent Director
Lead Independent Director
58.67K
+28.22%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
27.56K
+60.08%
Mr. Stephen J. DeNelsky
Mr. Stephen J. DeNelsky
Director
Director
26.56K
+62.34%
Mr. Robert Benson
Mr. Robert Benson
Independent Director
Independent Director
--
--
Mr. Sandy Martin
Mr. Sandy Martin
Investor Relations
Investor Relations
--
--
Mr. Mark Frost
Mr. Mark Frost
Interim Chief Financial Officer, Treasurer
Interim Chief Financial Officer, Treasurer
--
--

常見問題

Harvard Bioscience Inc的前五大股東是誰?

Harvard Bioscience Inc的前五大股東如下:Ms. Katherine Anne Eade, J.D.

有多少機構持有Harvard Bioscience Inc(HBIO)的股份?

截至2026Q1,共有201家機構持有Harvard Bioscience Inc的股份,合計持有的股份價值約為2.44M,占公司總股份的54.17% 。與2025Q4相比,機構持股有所增加,增幅為-447956.00。

哪個業務部門對Harvard Bioscience Inc的收入貢獻最大?

在2026Q1,Instruments, equipment, software and accessories業務部門對Harvard Bioscience Inc的收入貢獻最大,創收78.26M,占總收入的90.42% 。
tradingkey.logo
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有